APPLICATION NUMBER:

204629Orig1s000

OFFICE DIRECTOR MEMO
Summary Basis for Regulatory Action

Date: August 1, 2014
From: Curtis J Rosebraugh, MD, MPH
       Director, Office of Drug Evaluation II
Subject: Summary Review
NDA/BLA # Supp #: 204629
Applicant Name: Boehringer Ingelheim Pharmaceuticals Inc.
Proprietary / Established (USAN) Names:
   Jardiance
   Empagliflozin
Dosage Forms / Strength: 10 and 25 mg tablets
Proposed Indication(s): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Action: Approval

1. Introduction and Discussion

This will be a brief summary of the basis for the regulatory action regarding empagliflozin and the reader should review the action package for more detail. During the first review cycle, the safety and efficacy of empagliflozin were established that would allow marketing. However, deficiencies were identified at the manufacturing site which led to a Complete Response (CR) action on March 4, 2014.

These deficiencies have now been satisfactorily resolved. Therefore this application should receive an Approval action.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CURTIS J ROSEBRAUGH
08/01/2014